首页> 外文OA文献 >Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

【2h】

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

机译：疗效和循环肿瘤DNA（CTDNA）分析BRAF抑制剂DABRAFENIB（D），MEK抑制剂TRAMETINIB（T），患者（PTS）中的抗EGFR抗体Panitumumab（P），BRAF V600E突变（BRAFM）转移性结直肠癌（MCRC）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
R.B. Corcoran; T. André; T. Yoshino; J.C. Bendell; C.E. Atreya; J.H.M. Schellens; M.P. Ducreux; A. McRee; S. Siena; G. Middleton; M. Gordon; Y. Humblet; K. Muro; E. Elez; R. Yaeger; R. Sidhu; M. Squires; S. Jaeger; F. Rangwala; E. Van Cutsem;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib [J] . Marks Asher M., Bindra Ranjit S., DiLuna Michael L., Pediatric blood & cancer . 2018,第5期

机译：对BRAF / MEK抑制剂DabrafeNib / Trametinib的反应与BRAF V600E突变的Anplablastic Ganglioglioma不耐受vemureafenib
2. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer [J] . Middleton Gary, Yang Yiqun, Campbell Catarina D., Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第11期

机译：BRAF-突变体转录亚型预测结合BRAF，MEK和EGFR障碍的结合BRAF，TRAMETINIB和胰岛素，在结肠直肠癌患者中预测
3. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) [J] . Igor Puzanov Journal of Translational Medicine . 2015,第SUPPLEMENTa1期

机译：结合靶向治疗和免疫治疗：BRAF抑制剂dabrafenib（D）±MEK抑制剂曲美替尼（T）与ipilimumab（Ipi）联合治疗V600E / K突变阳性的不可切除或转移性黑色素瘤（MM）
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Comparative Analysis on Innate Immune System Function in Metastatic Breast, Colorectal, and Prostate Cancer Patients with Circulating Tumor Cells [D] . Santos, Mark Anthony Francisco. 2014

机译：转移性乳腺癌，结直肠癌和前列腺癌患者循环肿瘤细胞先天免疫系统功能的比较分析
6. Comparative safety of BRAF and MEK inhibitors (vemurafenib dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma [O] . Ana Cebollero, Teresa Puértolas, Isabel Pajares, -1

机译：BRAF和MEK抑制剂（vemurafenibdabrafenib和曲美替尼）在BRAF突变的转移性黑色素瘤一线治疗中的比较安全性
7. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer [O] . Gary Middleton, Yiqun Yang, Catarina D. Campbell, 2020

机译：BRAF-突变体转录亚型预测结合BRAF，MEK和EGFR障碍的结合BRAF，TRAMETINIB和胰岛素，在结肠直肠癌患者中预测

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

著录项

引文网络

相似文献

相关主题

期刊订阅